GVR Report cover Transdermal Drug Delivery Systems Market Size, Share & Trends Report

Transdermal Drug Delivery Systems Market Size, Share & Trends Analysis Report By Technology (Electroporation, Iontophoresis, Ultrasound), By Application (Pain Management, CNS, Hormone), By Region, And Segment Forecasts, 2023 - 2030

  • Report ID: GVR-1-68038-062-0
  • Number of Pages: 120
  • Format: Electronic (PDF)
  • Historical Range: 2018 - 2021
  • Industry: Healthcare

Report Overview

The global transdermal drug delivery system market was valued at USD 59.4 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 11.9% from 2023 to 2030. The transdermal drug delivery system market is majorly driven by the increasing prevalence of chronic diseases, where conventional drug delivery system, such as oral drugs has lower potency due to the hepatic first-pass metabolism.

Italy Trandermal Drug Delivery System Market Size, by technology, 2020 - 2030 (USD Billion)

COVID-19 had a slight negative impact on the transdermal drug delivery system market. Factors such as government-led restrictions and guidelines created a huge gap in the demand-supply chain leading to a fall in sales of transdermal drug delivery systems. Moreover, reduced patient visits to healthcare facilities also resulted in a reduced number of prescribed medicines which had a negative impact on the market.

However, the economies opening up and pharma companies constantly working on developing new drugs through a rise in R&D investments are driving the growth of the transdermal drug delivery system market. Increasing awareness and a rise in the allocation of funds towards healthcare by the governments of various countries represent lucrative growth opportunities during the forecast period.

The efficacious nature of these devices can be attributed to the heightened drug diffusion capabilities over conventional routes of drug delivery, namely oral, intravenous, and pulmonary. Additionally, a significant contributor to market growth is the increasing inclination of patients as well as physicians toward pain-free drug delivery, which is further presumed to drive the market demand during the forecast period. These aforementioned factors are expected to widen the scope for growth throughout the forecast period.

Moreover, the rising patient preference for pain-free drug administration has led to a significant surge in the adoption rate of adhesive skin patches that administer drugs, which is anticipated to present the market with high growth potential. In addition, the incorporation of transdermal systems will promote self-reliance in patients through a significant reduction in the frequency of hospital visits and cumulative treatment costs.

The emergence of technological innovations, such as the inclusion of microneedles or mechanical arrays in transdermal patches, is expected to provide the market with lucrative growth opportunities during the coming years. The advancements include modifications in transdermal patch designs, incorporation of pressure-sensitive adhesives, and permeation enhancers, which have resulted in enhanced drug diffusion and increased capacity to hold a greater amount of drug in the reservoir. Moreover, other innovations comprise miniaturized and advanced transdermal patches and reservoir-type transdermal patches, which deliver accurate medication dosage.

Technology Insights

The iontophoresis segment dominated the market in 2022 owing to technological advancements. Moreover, it promotes the movement of ions across the membrane under the influence of a small externally applied potential difference, which has been proven to enhance skin penetration and increase the release rate of several drugs with poor absorption/permeation profiles.

The mechanical arrays segment is anticipated to grow at a lucrative rate of more than 12.9% throughout the forecast period. An increasing number of product launches by prominent industry players and the numerous microneedle or mechanical array transdermal products in the late phases of clinical trials exemplify the high growth potential possessed by this segment.

Application Insights

The pain management segment held the highest share of 22.5% in 2022. This is due to the increasing usage of transdermal drug delivery systems in pain management that may have been caused due to various situations. The CNS segment held the second highest share owing to the rising prevalence of these disorders globally. For instance, according to the Pan American Health Organization, in 2019, neurological disorders accounted for 8.2 million lived with disability in the U.S.

Global Transdermal Drug Delivery System Market Share, By Application, 2022 (%)

The cardiovascular segment is expected to expand at an exponential CAGR of more than 13.1% during the forecast period. This exponential growth can be attributed to the increasing utilization of these systems in the treatment of angina pectoris, hypertension, and congestive heart failure. For instance, the advent of clonidine, nitroglycerin, and isosorbide dinitrate transdermal systems, used in the treatment of hypertension, have proven to be highly efficacious in treating complicated as well as uncomplicated treatment phases.

Regional Insights

North America held a sizeable share of more than 58.2% in 2022. The growth in this region is majorly driven by patent expirations, resulting in more companies entering the market. In addition, repositioning of previously failed drugs, reformulation of existing drug compounds, and huge investments undertaken by the prominent as well as new market entrants are also presumed to be the key factors responsible for the substantial share captured by this region.

Transdermal Drug Delivery Systems Market Trends by Region

Factors such as favorable reimbursement scenarios and rising awareness by government organizations in Europe are contributing to the growth of the transdermal drug delivery system market in the region. Well-developed healthcare structure that covers the healthcare costs of the citizens, promotes more people opting for treatment in the region. This is expected to further boost the market growth during the forecast period.

The Asia Pacific market is anticipated to exhibit the fastest CAGR of above 13.4% during the forecast period, attributable to the growing healthcare spending and the rapidly evolving healthcare infrastructure. In addition, the growth is due to the high research and development intensity as well as the growing awareness in emerging economies, such as China and India.

Key Companies & Market Share Insights

Key players in the transdermal drug delivery system market carry out various strategic initiatives such as mergers & acquisitions, partnership & collaboration, and expansion. Key players in the market are also focusing on launching new products to expand their market presence and acquire a strong position in the market. For instance, in September 2022, Biomind Labs and Queen’s University of Belfast receive a controlled substances license to commence the production of a novel transdermal drug delivery system. Some of the prominent players in the global transdermal drug delivery system market include:

  • Novartis AG

  • Johnson & Johnson

  • Mylan Pharmaceuticals, Inc.

  • Boehringer Ingelheim GmbH

  • Biogel Technology, Inc.

  • Transdermal Technologies, Inc.

  • Skyepharma, Watson Pharmaceuticals, Inc.

  • 3M Company

  • Noven Pharmaceuticals, Inc.

  • 4P Therapeutics, LLC

  • Transdermal Corporation

  • Echo Therapeutics, Inc.

 Transdermal Drug Delivery System Market Report Scope

Report Attribute


Market size value in 2023

USD 66.20 billion

Revenue forecast in 2030

USD 145.0 billion

Growth Rate

CAGR of 11.9% from 2023 to 2030

Base year for estimation


Historical data

2018 - 2021

Forecast period

2023 - 2030

Quantitative units

Revenue in USD million, CAGR from 2022 to 2030

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Technology, application, region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; South Korea; Australia; Thailand; India; Japan; China; South Korea; Mexico; Brazil; Argentina; South Africa; Saudi Arabia; UAE; Kuwait

Key companies profiled

Novartis AG; Johnson & Johnson; Mylan Pharmaceuticals, Inc.; Boehringer Ingelheim GmbH; Biogel Technology, Inc.; Transdermal Technologies, Inc.; Skyepharma; Watson Pharmaceuticals, Inc.; 3M Company; Noven Pharmaceuticals, Inc.; 4P Therapeutics, LLC; Transdermal Corporation; Echo Therapeutics, Inc.

Customization scope

Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Global Transdermal Drug Delivery Systems Market Segmentation

This report forecasts revenue growth at global, regional, and country levels along with provides an analysis on the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global Transdermal Drug Delivery System Market report based on the technology, application, and region:

Global Transdermal Drug Delivery Systems Market Segmentation

  • Technology Outlook (Revenue in USD Million, 2018 - 2030)

    • Electroporation

    • Radio Frequency

    • Iontophoresis

    • Microporation

    • Thermal

    • Mechanical arrays

    • Ultrasound

    • Others 

  • Application Outlook (Revenue, USD Million, 2018 - 2030)

    • CNS

    • Pain Management

    • Cardiovascular

    • Hormone

    • Immunological

    • Metabolic

    • Gastrointestinal

    • Infection

    • Cancer

    • Others

      • Urological

      • Blood disorders

      • Respiratory

      • Musculoskeletal

  • Regional Outlook (Revenue, USD Million, 2018 - 2030)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • U.K.

      • France

      • Italy

      • Spain

      • Denmark

      • Sweden

      • Norway

    • Asia Pacific

      • Japan

      • India

      • China

      • South Korea

      • Thailand

      • Australia

    • Latin America

      • Brazil

      • Mexico

      • Argentina

    • Middle East & Africa

      • South Africa

      • Saudi Arabia

      • UAE

      • Kuwait

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now

ESOMAR Certified Member Great Place to Work Certified

ESOMAR & Great Work to Place Certified

ISO 9001:2015 & 27001:2022 Certified

ISO 9001:2015 & 27001:2022 Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.